AiM Medical Robotics closes $8.1M Series A for MRI-guided neurosurgery

AiM Medical Robotics has closed an $8.1 million Series A co-led by IQ Capital and 1540 Ventures to fund its first-in-human clinical study and development of an MRI-compatible neurosurgical robot. Announced on 30 September 2025, the round includes $3.75 million of notes converted into equity and had an initial close in June. AiM reports more than $11.3 million in investment to date, alongside federal grant support for the underlying technology.

The compact, portable system is designed to align surgical instruments while the surgeon receives continuous MRI images. Its initial application is positioning deep-brain-stimulation leads, including procedures for Parkinson’s disease. Performing instrument guidance within the scanner is intended to let the team account for changes in brain position during surgery and follow the instrument against updated images.

AiM also identifies biopsy, tumour and epilepsy ablation, and targeted intracranial drug delivery as intended applications. The common requirement is accurate access to a selected location in the brain, with imaging available during the intervention. Product development is focused on fitting actuated alignment into established clinical workflows and progressing the platform through clinical and regulatory milestones.

AiM had announced a research collaboration with Brigham and Women’s Hospital in May 2024, targeting a first human study in the hospital’s AMIGO imaging suite. It also reported a cadaver trial placing bilateral stimulation leads with live MRI guidance and an agreement to integrate Synaptive Medical’s Modus Nav software. Those earlier studies and navigation interfaces underpin the clinical programme receiving Series A funding.

Investors include Worcester Polytechnic Institute, the Sontag Innovation Fund and Cancer Research Horizons, alongside angel groups including New York Angels, Harvard Business School Alumni Angels and SWAN Impact Network. The cancer-focused participation connects the financing with AiM’s planned biopsy and therapy-delivery applications. Proceeds will also support strategic partnerships and the first patient study as the Worcester, Massachusetts company advances its device toward clinical use.